Inovio Pharmaceuticals (NASDAQ:INO), the International Vaccine Institute, and Seoul National University Hospital announce a partnership to start a Phase 1/2 clinical trial of Inovio’s COVID-19 vaccine INO-4800 in South Korea.
The 2nd-stage trial of INO-4800 will assess the
safety, tolerability, and immunogenicity of the candidate vaccine in 40
healthy adults aged 19-50 years, and will further expand to enroll an
additional 120 people aged 19-64 years.
The trial is expected to start later in June.
https://seekingalpha.com/news/3580328-inovio-to-begin-phase-1-2-trial-of-covidminus-19-dna-vaccine-in-south-korea
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.